Topical anti-microbial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild-to-moderate atopic dermatitis in a phase 2 randomized controlled trial.
van der Kolk, Tessa Niemeyer, Buters, Thomas P., Krouwels, Lara, Boltjes, Jiry, de Kam, Marieke L., van der Wall, Hein, van Alewijk, Dirk C.J.G., van den Munckhof, Ellen H.A., Becker, Martin J., FeissJournal:
Journal of the American Academy of Dermatology
DOI:
10.1016/j.jaad.2020.08.132
Date:
October, 2020
File:
PDF, 1.33 MB
2020
File converter
More search results
More benefits 
